DiPLA

DiPLA is not known to have been assessed in humans. ==Interactions==

Pharmacodynamics In an early study, DiPLA showed 23.2% of the antiserotonergic activity of LSD in the isolated rat uterus and hence was about 4-fold less potent than LSD in this assay. Subsequently, DIPLA was reported to have an affinity (Ki) for the serotonin 5-HT2A receptor of 9.0 to 20.2nM, which was about 4- to 9-fold lower than that of LSD (Ki = 4.8nM). It is an agonist of the serotonin 5-HT2A receptor and also interacts with other receptors such as the serotonin 5-HT1A receptor, the serotonin 5-HT2C receptor, and dopamine receptors. ==History==

DiPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s and thereafter. ==See also==